Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
REDWOOD CITY, Calif., May 30, 2017 -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that management will present at two upcoming investment conferences:
- 14th Annual Craig-Hallum Institutional 1x1 Investor Conference on Wednesday, May 31st at The Depot Renaissance Minneapolis Hotel in Minneapolis.
- Jefferies 2017 Global Healthcare Conference on Thursday, June 8, at 2:30 p.m. Eastern time (11:30 a.m. Pacific time). The conference will be held in New York City.
A live webcast and replay of the presentation at the Jefferies Global Healthcare Conference will be available on the Investors section of the company’s website, http://ir.codexis.com/.
About Codexis, Inc.
Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals, as well as the development of enzymes as biotherapeutics and for molecular diagnostics. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see www.codexis.com.
Contacts: Investors LHA Jody Cain, 310 691 7100 [email protected]
